The Malmö International Brother Study (MIBS)

NCT00231751 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2005-10-04

No results posted yet for this study

Summary

Existing data support the concept that a genetic predisposition for inhibitor development exists. The aim of the Malmö International Brother Study (MIBS) is to evaluate genetic factors associated with the development of inhibitory antibodies in patients with hemophilia.

Conditions

  • Hemophilia A With Inhibitors

Sponsors & Collaborators

  • Skane University Hospital

    lead OTHER

Principal Investigators

  • Jan Astermark, M.D., Ph.D. · Skane University Hospital

Eligibility

Min Age
0 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Completion
2004-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00231751 on ClinicalTrials.gov